Lyell Immunopharma
LYEL
105 hedge funds and large institutions have $95.9M invested in Lyell Immunopharma in 2024 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 33 increasing their positions, 25 reducing their positions, and 32 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
32% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 25
10% more call options, than puts
Call options by funds: $11K | Put options by funds: $10K
0.06% more ownership
Funds ownership: 2.51% → 2.57% (+0.06%)
10% less funds holding
Funds holding: 117 → 105 (-12)
34% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 32
46% less capital invested
Capital invested by funds: $177M → $95.9M (-$80.7M)
Top Buyers
| 1 |
DC
Decheng Capital
Menlo Park,
California
|
+$11.8M |
| 2 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$8.06M |
| 3 |
VP
venBio Partners
San Francisco,
California
|
+$7.04M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.72M |
| 5 |
Renaissance Technologies
New York
|
+$1.4M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$2.96M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.93M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.65M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1,000K |
| 5 |
HF
HRT Financial
New York
|
-$785K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Mariner
Overland Park,
Kansas
| – | -$19.4K | -704 | Closed |
|
127
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$18.4K | -665 | Closed |
|
|
AG
128
Algert Global
San Francisco,
California
| – | -$18K | -638 | Closed |
|
|
PD
129
Point72 (DIFC)
Dubai,
United Arab Emirates
| – | -$4.9K | -178 | Closed |
|
|
GRP
130
Global Retirement Partners
San Rafael,
California
| – | -$4.27K | -155 | Closed |
|
|
TWD
131
True Wealth Design
Akron,
Ohio
| – | -$432 | -16 | Closed |
|
|
SAM
132
Smartleaf Asset Management
Boston,
Massachusetts
| – | -$403 | -13 | Closed |
|
|
CPA
133
Capital Performance Advisors
Walnut Creek,
California
| – | -$236 | -9 | Closed |
|
|
AAP
134
Arax Advisory Partners
Denver,
Colorado
| – | -$132 | -5 | Closed |
|
|
C
135
Covestor
London,
United Kingdom
| – | +$40 | +2 | +100% |
|
136
Simplex Trading
Chicago,
Illinois
| – | +$615 | +31 | New |
|
LYEL Hedge Fund Activity: Q4 2024 in Review
105 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q4 2024, worth a combined $95.9M — down 46% from $177M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of LYEL and 21 opened new positions — a net loss of 11 holders — while 25 trimmed existing stakes and 33 added.
The largest buyer was Decheng Capital, opening a new position worth an estimated $11.8M. The largest seller was OrbiMed, cutting an estimated $2.96M.
- 105 institutional investors held Lyell Immunopharma (LYEL) as of Q4 2024, down from 117 in Q3 2024.
- Funds reported $95.9M of Lyell Immunopharma stock for Q4 2024, down 46% quarter-over-quarter.
- 21 funds opened new Lyell Immunopharma positions in Q4 2024 and 32 closed out, a net change of -11 holders.
- The largest Lyell Immunopharma buyer in Q4 2024 was Decheng Capital, an estimated $11.8M added.
- The largest Lyell Immunopharma seller in Q4 2024 was OrbiMed, an estimated $2.96M sold.
Based on aggregated 13F filings for Q4 2024.